The mechanism of action of PGBx in RLM oxidative phosphorylation was studied by varying the sequence of addition of PGB X . When PGB X was added to RLM preexposed to hypotonic media at 27° no restoration of phosphorylation was observed. When RLM were exposed to hypotonic conditions for 30 seconds before the addition of PGBx and subsequently exposed to hypotonic conditions, the resulting phosphorylation was 60% of that observed in the normal system. From these results it is concluded that PGBx functions in the in vitro PGB X RLM assay system as a "protective" agent rather than a "restorative" agent. 
INTRODUCTION
The possible use of PGB X (1, 2, 3) as a therapeutic agent in the treatment of human ischemic diseases was suggested by the favorable results from only a few animal experiments (4, 5, 6, 7, 8, 9, 10) . Obviously before any human trials may be undertaken much more animal testing must be completed, and in addition, certain basic information concerning the mechanism of action of this drug must be known. At this stage of our knowledge of PGB X biochemistry, the possibility of successful elucidation of the in vivo mechanism of action appears remote. However, since the elucidation of the in vitro mechanism of PGB X might reveal an insight as to the in vivo mechanism, studies have been underway in this laboratory to define the in vitro PGB X effect.
Recently we reported that PGB X ineracts with BSA (11) to form a complex that was inactive in the in vitro PGB X assay system (2, 3). Some of the experimental evidence published in that report was based on altering the sequence of the addition of PGB X and BSA in the assay system so that the PGB X and BSA could react before the addition of RLM. The results of these experiments then suggested the importance of the sequence of addition of the reactants of the test system, and that by studying this in detail some information concerning the mechanism of the in vitro PGB X effect might be realized.
EXPERIMENTAL
Materials and Methods: PGB X Type II was synthesized and assayed for the in vitro PGB X effect as reported by Polis et al (2, 3) . RLM was isolated and stored at 0° as described previously (2, 3) . In this study the RLM were aged three days before use. All analytical methods used in this study were described previously (2, 3).
Note: Abbreviations used in this report are: RLM, rat liver mitochondria; BSA, bovine serum albumin; Pi, inorganic phosphate
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Results: The effect of varying the order of addition of PGB X to the in vitro PGB X assay system was studied by measuring the changes in phosphorylating ability of RLM under various experimental conditions. Table I lists the composition and experimental conditions for the in vitro PGB X assay system (2). In the normal PGB X assay system, RLM were added to the hypotonic medium (Mixture A, Table I ) containing the requisite amount of PGB X , and the mixture then incubated for the required time period. Phosphate acceptor (Mixture B, Table I ) was then added and the mixture again incubated for 20 minutes. At the end of this time period the solution was deproteinized and the Pi esterfied was measured. The extent of phosphorylation by this system was compared to that resulting from the following changes in experimental protocol: (a) RLM were incubated in Mixture A in the absence of PGB X for the required time period; at the end of this incubation period PGB X was added followed by the addition of Mixture B; the assay was then continued as above, (b) RLM was added to Mixture A and incubated for 30 seconds; PGB X was then added and the hypotonic incubation continued for the required time period; at the end of the incubation period Mixture B was added and the assay continued as above. Figure I shows the results of these tests. The curves shown are described in the legend of the figure. The normal assay curve of PGB X concentration shows the usual biphasic response with the maximum phosphorylation in the range of 2-10 ug/ml of reaction. When RLM were incubated in Mixture A in the absence of PGB X , the subsequent addition of PGB X did not restore the phos-_ phorylation ability of the degraded RLM. When PGB X was added to the RLM incubated in Mixture A for 30 seconds, a biphasic phosphorylation curve was observed, however the maximum phosphorylation ability was only about 2/3 of the normal assay and in addition was shifted so that 10-20 ug PGB x /ml reaction were required.
DISCUSSION
In earlier reports on the physiological mechanism of PGB X action in both in vitro and in vivo systems it was suggested that PGB X functioned to reactivate damaged mitochondria (1, 2, 3, 8, 12) and thus reverse the pathological effects of ischemia. This interpretation appears contrary to the results reported in this study with isolated RLM subjected to hypotonic degradation. The results reported here show that RLM exposed to hypotonic media at 27 show a reduced capacity for oxidative phosphorylation. However when RLM are exposed to hypotonic media at 27° containing the required amount of PGB X , they maintain their capacity for oxidative phosphorylation. This phenomenon is the in vitro PGB X effect on RLM. In contrast when RLM are exposed to hypotonic media at 27°, the subsequent addition of PGBx has no effect on the recovery of phosphorylation activity of these RLM.
From the above results it may be concluded that PGB X functions in the in vitro assay system as a'^protective' agent for RLM capacity for phosphorylation, rather than a "restorative" agent that reverses the degradative effects of exposure of RLM to hypotonic conditions. 
